Rural Medicine Australia 2018

DermaSensor showcases ground-breaking skin cancer evaluation concept at Rural Medicine Australia Conference in Darwin

DARWIN, Australia, 25th October 2018: Today, DermaSensor, the medical device company that seeks to enable healthcare professionals to efficiently check for skin cancer, presents its ground-breaking technology concept at the Rural Medicine Australia Conference in Darwin.

This annual conference and research/scientific health forum is hosted by the Australian College of Rural and Remote Medicine (ACRRM) and the Rural Doctors Association of Australia (RDAA). Nearly 500 rural doctors, medical students and other rural health stakeholders from across the country are expected to attend.

Rural Medicine Australia 2018 aims to educate and inform rural health professionals including junior doctors, students, educators, academics, and medical practitioners who are passionate about generalist medicine in rural and remote communities.

Tori Fox, Marketing Manager ANZ, Christian Orb, Commercial Director, ANZ and Palak Bhatnagar (Associate Manager of Medical and Business Development ) from the DermaSensor Team are in attendance conducting market research into the use-case for the DermaSensor device concept, a revolutionary, world-first technology, designed to augment clinician decision making by providing accurate differentiation between malignant and benign skin lesions.

“We are delighted to be exhibiting DermaSensor’s technology concept and presenting how it can help rural doctors efficiently check for skin cancer,” explains Christian Orb, Commercial Director, ANZ. “We look forward to meeting key stakeholders and health professionals to introduce the concept of a skin health service that’s efficient, accurate and affordable,” Mr. Orb says.

This exciting breakthrough was achieved using Elastic Scattering Spectroscopy – a technology pioneered at Boston University and University College London that uses light to evaluate cellular and subcellular structures of the skin.

The device is undergoing FDA and TGA approval and is expected to be available in Australia in late-2020. This low-cost, easy-to-use device enables healthcare providers and patients to access fast, accurate skin lesion assessments to ultimately improve outcomes for patients with skin cancer.

DermaSensor aims to improve the way general practitioners assess the skin. The handheld DermaSensor device takes five quick recordings via non-invasive sub-cellular scans. This provides an immediate, objective result that’s typically more accurate than visual assessment alone.

Its speed and ease of use improves workflow by extending lesion identification and evaluation to trained team members. Patients can expect to experience fewer unnecessary complications or side effects and medical practitioners may spend less time on lengthy procedures.

Scroll to Top